REGN5458 Elicits Early, Sustainable Responses in Heavily Pretreated Multiple Myeloma
June 13th 2022The bispecific antibody REGN5458 elicited rapid responses that were further characterized by their depth, durability, and low incidence of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.
Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma
June 5th 2022Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.
Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care
May 31st 2022The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.
Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma
According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.
FDA Approval of Cilta-Cel Fast Tracks Multiple Myeloma Toward Curative Potential
March 7th 2022Sundar Jagannath, MBBS, discusses the significance of the FDA approval of ciltacabtagene autoleucel, important adverse effects to be aware of, and shared his thoughts on where the treatment fits into the current and future treatment paradigms.
Bispecific Antibodies Show Potential After Relapse on CAR T-cell Therapy in Myeloma
Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.